File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study

TitleFrequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study
Authors
Issue Date2011
PublisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/13651501.asp
Citation
International Journal of Psychiatry in Clinical Practice, 2011, v. 15 n. 2, p. 80-90 How to Cite?
AbstractBACKGROUND: In randomised controlled trials, the frequency of treatment-emergent sexual dysfunction (TESD) in patients with major depressive disorder (MDD) at week 8 was lower with duloxetine than selective serotonin reuptake inhibitor (SSRI) therapy. METHODS: This 6-month, prospective, observational study compared the frequency of TESD (using the Arizona Sexual Experience [ASEX] scale) in MDD patients treated with duloxetine or SSRI monotherapy in the first 8 weeks in normal clinical practice. RESULTS: Physician-assessed TESD frequency at week 8 was comparable with duloxetine and SSRI monotherapy (23.9 and 26.2%, respectively; P = 0.545). Improvements in Clinical Global Impressions of Severity (CGI-S), 16-item Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR(16)), Integral Inventory for Depression (IID) total scores and remission rates were statistically significantly greater with duloxetine than SSRI monotherapy (P < 0.001, 0.010, <0.001, and 0.002, respectively), but TESD attenuated improvements in quality of life measures (EuroQoL questionnaire-5 dimensions [EQ-5D] and Sheehan Disability Scale [SDS] scores:
Persistent Identifierhttp://hdl.handle.net/10722/135424
ISSN
2015 Impact Factor: 1.278
2015 SCImago Journal Rankings: 0.493
ISI Accession Number ID
Funding AgencyGrant Number
Eli Lilly and Company
Funding Information:

Study sponsorship was provided by Eli Lilly and Company. The authors would like to thank Professor Pedro Delgado (Department of Psychiatry, School of Medicine, University of Texas, Texas, US), Margaret McBride (formerly of Intercontinental Information Services, Eli Lilly Australia Pty Ltd), Adam Meyers (Eli Lilly and Company) and Jo Wood (Meditech Media Asia Pacifi c Pty Ltd) for assistance with the study design, study description document, data analysis and provision of writing support, respectively. The contributions of all of the investigators, assistants and patients that participated in this study are also gratefully acknowledged.

 

DC FieldValueLanguage
dc.contributor.authorDueñas, Hen_US
dc.contributor.authorLee, Aen_US
dc.contributor.authorBrnabic, AJMen_US
dc.contributor.authorChung, KFen_US
dc.contributor.authorLai, CHen_US
dc.contributor.authorBadr, MGen_US
dc.contributor.authorUy-Ponio, Ten_US
dc.contributor.authorRuiz, JRen_US
dc.contributor.authorVarrey, Pen_US
dc.contributor.authorJian, Hen_US
dc.contributor.authorDossenbach, Men_US
dc.date.accessioned2011-07-27T01:34:58Z-
dc.date.available2011-07-27T01:34:58Z-
dc.date.issued2011en_US
dc.identifier.citationInternational Journal of Psychiatry in Clinical Practice, 2011, v. 15 n. 2, p. 80-90en_US
dc.identifier.issn1365-1501-
dc.identifier.urihttp://hdl.handle.net/10722/135424-
dc.description.abstractBACKGROUND: In randomised controlled trials, the frequency of treatment-emergent sexual dysfunction (TESD) in patients with major depressive disorder (MDD) at week 8 was lower with duloxetine than selective serotonin reuptake inhibitor (SSRI) therapy. METHODS: This 6-month, prospective, observational study compared the frequency of TESD (using the Arizona Sexual Experience [ASEX] scale) in MDD patients treated with duloxetine or SSRI monotherapy in the first 8 weeks in normal clinical practice. RESULTS: Physician-assessed TESD frequency at week 8 was comparable with duloxetine and SSRI monotherapy (23.9 and 26.2%, respectively; P = 0.545). Improvements in Clinical Global Impressions of Severity (CGI-S), 16-item Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR(16)), Integral Inventory for Depression (IID) total scores and remission rates were statistically significantly greater with duloxetine than SSRI monotherapy (P < 0.001, 0.010, <0.001, and 0.002, respectively), but TESD attenuated improvements in quality of life measures (EuroQoL questionnaire-5 dimensions [EQ-5D] and Sheehan Disability Scale [SDS] scores: </=0.012). Several factors were significantly (P </= 0.05) associated with TESD at week 8 in this study. CONCLUSIONS: TESD rates with duloxetine and SSRIs at week 8 were comparable, however, significant differences in effectiveness were observed in favour of duloxetine. Antidepressant tolerability with respect to TESD must be managed to maximize remission of depressed patients.-
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/13651501.asp-
dc.relation.ispartofInternational Journal of Psychiatry in Clinical Practiceen_US
dc.rightsInternational Journal of Psychiatry in Clinical Practice. Copyright © Informa Healthcare.-
dc.subject.meshAdrenergic Uptake Inhibitors - adverse effects - pharmacology-
dc.subject.meshDepressive Disorder, Major - drug therapy-
dc.subject.meshSerotonin Uptake Inhibitors - adverse effects - pharmacology-
dc.subject.meshSexual Dysfunctions, Psychological - chemically induced-
dc.subject.meshThiophenes - adverse effects - pharmacology-
dc.titleFrequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational studyen_US
dc.typeArticleen_US
dc.identifier.emailChung, KF: kfchung@hkucc.hku.hken_US
dc.identifier.authorityChung, KF=rp00377en_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.3109/13651501.2011.572169-
dc.identifier.pmid22121855-
dc.identifier.scopuseid_2-s2.0-79955783327-
dc.identifier.hkuros187466en_US
dc.identifier.volume15en_US
dc.identifier.issue2en_US
dc.identifier.spage80en_US
dc.identifier.epage90en_US
dc.identifier.isiWOS:000290270900002-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats